Finance

Lists
Why is COAG down 6.96%?
Dive Deeper
COAG:NASDAQ
Hemab Therapeutics Holdings Inc
$39.83
-6.96%
(-2.98) 1D
Nov 10, 12:53:34 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for COAG...
Open
$40.09
High
$44.15
Low
$39.51
Mkt. cap
1.86B
Avg. vol.
472.69K
Volume
259.58K
52-wk high
$55.42
52-wk low
$23.00
No. of employees
72
Open
$40.09
High
$44.15
Low
$39.51
Mkt. cap
1.86B
Avg. vol.
472.69K
Volume
259.58K
52-wk high
$55.42
52-wk low
$23.00
No. of employees
72
News stories
From web sources and news partners
About Hemab Therapeutics Holdings Inc
CEO-
Employees72
Founded2020
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitehemab.com
Analyst ratings
Based on 5 analysts giving stock ratings to COAG in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for COAG in the last 3 months.
Highest
Current $39.83
$70.00 (+75.75%)
Average
$63.00 (+58.17%)
Lowest
$56.00 (+40.60%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gaurav Maini
LifeSci Capital
Buy
Initiated
$65.00
+63.2%
11/09/2026
David Nierengarten
Wedbush
Buy
Maintained
$64.00
+60.7%
11/05/2026
Joyce Zhou
J.P. Morgan
Buy
Initiated
$70.00
+75.7%
10/15/2026
Michael King
Rodman & Renshaw
Buy
Initiated
$56.00
+40.6%
10/12/2026
Emily Bodnar
H.C. Wainwright
Buy
Reiterated
$60.00
+50.6%
08/11/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
$46.00
+15.5%
07/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
$47.00
+18%
07/13/2026
Cory Kasimov
Evercore ISI
Buy
Initiated
$50.00
+25.5%
05/26/2026
Last report
Aug 11, 2026
Fiscal period
Q2 2026
-$0.80 / -$0.82
+2.04%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
14.10M
12.87M
19.46M
20.34M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.46M
3.18M
4.15M
5.74M
Operating expense
16.56M
16.06M
23.61M
26.08M
Total operating expenses
16.56M
16.06M
23.61M
26.08M
Operating income
-16.56M
-16.06M
-23.61M
-26.08M
Other non operating income
591.00K
2.22M
-282.00K
-832.00K
EBT including unusual items
-15.50M
-12.20M
-22.68M
-24.05M
EBT excluding unusual items
-15.50M
-13.50M
-22.68M
-24.05M
Income tax expense
-190.00K
4.00K
12.00K
97.00K
Effective tax rate
1.23%
-0.03%
-0.05%
-0.40%
Other operating expenses
-
-
-
-
Net income
-15.31M
-12.21M
-22.69M
-24.15M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-0.80
Interest and investment income
473.00K
335.00K
1.22M
2.86M
Interest expense
-
-
-
-
Net interest expenses
473.00K
335.00K
1.22M
2.86M
Depreciation and amortization charges
-
-
-
-
EBITDA
-16.48M
-15.98M
-23.54M
-26.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps